

RENALYTIX AI

8 November 2018

Renalytix AI plc
("Renalytix" or the "Company")

Director / PDMR shareholding

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence ("AI") enabled clinical diagnostic solutions for kidney disease, announces that it was yesterday notified that on 6 November 2018 the following PDMR undertook a transaction in the ordinary shares of 0.25 pence each in the capital of the Company ("Ordinary Shares"), at a price of 120 pence per Ordinary Share:

		<i>Number of Ordinary Shares bought</i>	<i>Resultant Interest in Ordinary Shares</i>	<i>Resultant Interest in Ordinary Shares (%)</i>
James McCullough	Chief Executive Officer	16,150	2,870,110	5.33

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	James R. McCullough
2	Reason for the notification	
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Renalytix AI plc
b)	LEI	213800NTOH3FK3WER551
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	

a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.25 pence each GB00BYWL4Y04				
b)	Nature of the transaction	Purchase of Ordinary Shares				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>120 pence</td> <td>16,150</td> </tr> </tbody> </table>	Price(s)	Volume(s)	120 pence	16,150
Price(s)	Volume(s)					
120 pence	16,150					
d)	Aggregated information - Aggregated volume - Price	n/a				
e)	Date of the transaction	06 November 2018				
f)	Place of the transaction	London Stock Exchange				

For further information, please contact:

Renalytix AI plc
James McCullough, CEO

www.renalytixai.com
Via Walbrook PR or Tel: +1 646 397 3970

N+1 Singer (Nominated Adviser & Broker)
Aubrey Powell / James White / George Tzimas (Corporate Finance)
Tom Salvesen / Ross Penney (Corporate Broking)

Tel: 020 7496 3000

Walbrook PR Limited
Paul McManus / Lianne Cawthorne

Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07980 541 893 / 07584 391 303